{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:23:09Z","timestamp":1793262189156,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-77246-4","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:46:06Z","timestamp":1732607166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["One year of ETI reduces lung bacterial colonisation in adults with cystic fibrosis"],"prefix":"10.1038","volume":"14","author":[{"given":"Lucile","family":"Mianowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dol\u00e9ans-Jordheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Barraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Rabilloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mael","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaele Nove","family":"Josserand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quitterie","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"17","key":"77246_CR1","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D. et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl. J. Med.379 (17), 1612\u20131620 (2018).","journal-title":"N Engl. J. Med."},{"issue":"9","key":"77246_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","volume":"385","author":"PJ Barry","year":"2021","unstructured":"Barry, P. J. et al. Triple therapy for cystic fibrosis Phe508del-Gating and -residual function genotypes. N Engl. J. Med.385 (9), 815\u2013825 (2021).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"77246_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","volume":"10","author":"S Sutharsan","year":"2022","unstructured":"Sutharsan, S. et al. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med.10 (3), 267\u2013277 (2022).","journal-title":"Lancet Respir Med."},{"issue":"10","key":"77246_CR4","doi-asserted-by":"publisher","first-page":"e167957","DOI":"10.1172\/JCI167957","volume":"133","author":"DP Nichols","year":"2023","unstructured":"Nichols, D. P. et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J. Clin. Invest.133 (10), e167957 (2023).","journal-title":"J. Clin. Invest."},{"issue":"2","key":"77246_CR5","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","volume":"62","author":"L Schaupp","year":"2023","unstructured":"Schaupp, L. et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur. Respir J.62 (2), 2202153 (2023).","journal-title":"Eur. Respir J."},{"key":"77246_CR6","unstructured":"VG Librairies [Internet]. [cited 2023 Dec 4]. REMIC: r\u00e9f\u00e9rentiel en microbiologie m\u00e9dicale. Soci\u00e9t\u00e9 fran\u00e7aise de microbiologie m\u00e9dicale. (2022). https:\/\/www.vg-librairies.fr\/sciences-fondamentales\/8653-remic-referentiel-en-microbiologie-medicale.html"},{"issue":"9","key":"77246_CR7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","volume":"180","author":"PA Flume","year":"2009","unstructured":"Flume, P. A. et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir Crit. Care Med.180 (9), 802\u2013808 (2009).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"1","key":"77246_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TWR Lee","year":"2003","unstructured":"Lee, T. W. R., Brownlee, K. G., Conway, S. P., Denton, M. & Littlewood, J. M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros.2 (1), 29\u201334 (2003).","journal-title":"J. Cyst. Fibros."},{"key":"77246_CR9","unstructured":"R Core Team. R A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna. - References - Scientific Research Publishing [Internet]. [cited 2023 Nov 30]. (2022). https:\/\/www.scirp.org\/(S(lz5mqp453ed%20snp55rrgjct55))\/reference\/referencespapers.aspx?referenceid=3456808"},{"issue":"3","key":"77246_CR10","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1067\/mic.2003.78","volume":"31","author":"L Saiman","year":"2003","unstructured":"Saiman, L. & Siegel, J. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am. J. Infect. Control. 31 (3), S6\u201362 (2003).","journal-title":"Am. J. Infect. Control"},{"issue":"6","key":"77246_CR11","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1183\/09031936.02.00268002","volume":"20","author":"A Jung","year":"2002","unstructured":"Jung, A. et al. Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients. Eur. Respir J.20 (6), 1457\u20131463 (2002).","journal-title":"Eur. Respir J."},{"issue":"7","key":"77246_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/ciac117","volume":"75","author":"AC Miller","year":"2022","unstructured":"Miller, A. C. et al. The Rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting Elexacaftor-Tezacaftor-Ivacaftor. Clin. Infect. Dis.75 (7), 1115\u20131122 (2022).","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"77246_CR13","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/ppul.26485","volume":"58","author":"C Gushue","year":"2023","unstructured":"Gushue, C. et al. Impact of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor on lung disease in cystic fibrosis. Pediatr. Pulmonol.58 (8), 2308\u20132316 (2023).","journal-title":"Pediatr. Pulmonol."},{"issue":"6","key":"77246_CR14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","volume":"21","author":"LM Sosinski","year":"2022","unstructured":"Sosinski, L. M., Neugebauer, H. C. M., Ghuneim, K. A., Guzior, L. A. J. & Castillo-Bahena, D. V. A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung. J. Cyst. Fibros.21 (6), 996\u20131005 (2022).","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"77246_CR15","doi-asserted-by":"publisher","first-page":"e01454","DOI":"10.1128\/spectrum.01454-22","volume":"10","author":"ST Pallenberg","year":"2022","unstructured":"Pallenberg, S. T. et al. Impact of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on the cystic fibrosis Airway Microbial Metagenome. Microbiol. Spectr.10 (5), e01454\u2013e01422 (2022).","journal-title":"Microbiol. Spectr."},{"issue":"5","key":"77246_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/ph15050606","volume":"15","author":"G Migliorisi","year":"2022","unstructured":"Migliorisi, G. et al. Elexacaftor-Tezacaftor-Ivacaftor as a final Frontier in the treatment of cystic fibrosis: definition of the clinical and microbiological implications in a case-control study. Pharmaceuticals. 15 (5), 606 (2022).","journal-title":"Pharmaceuticals"},{"issue":"5","key":"77246_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ppul.26362","volume":"58","author":"MR Beck","year":"2023","unstructured":"Beck, M. R., Hornick, D. B., Pena, T. A., Singh, S. B. & Wright, B. A. Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis. Pediatr. Pulmonol.58 (5), 1569\u20131573 (2023).","journal-title":"Pediatr. Pulmonol."},{"issue":"3","key":"77246_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ppul.26261","volume":"58","author":"S Sheikh","year":"2023","unstructured":"Sheikh, S. et al. Impact of elexacaftor\u2013tezacaftor\u2013ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis. Pediatr. Pulmonol.58 (3), 825\u2013833 (2023).","journal-title":"Pediatr. Pulmonol."},{"issue":"8","key":"77246_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","volume":"78","author":"M Casey","year":"2023","unstructured":"Casey, M. et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax. 78 (8), 835\u2013839 (2023).","journal-title":"Thorax"},{"key":"77246_CR20","doi-asserted-by":"crossref","unstructured":"Wiesel, V. et al. Eradication of Nontuberculous Mycobacteria in people with cystic fibrosis treated with Elexacaftor\/Tezacaftor\/Ivacaftor: a Multicenter Cohort Study. J. Cyst. Fibros. ;S1569199323001339. (2023).","DOI":"10.1183\/13993003.congress-2023.OA1542"},{"issue":"5","key":"77246_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/cid\/ciu944","volume":"60","author":"SL Heltshe","year":"2015","unstructured":"Heltshe, S. L. et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin. Infect. Dis. Off Publ Infect. Dis. Soc. Am.60 (5), 703\u2013712 (2015).","journal-title":"Clin. Infect. Dis. Off Publ Infect. Dis. Soc. Am."},{"key":"77246_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fcimb.2020.00213","volume":"10","author":"AL Welp","year":"2020","unstructured":"Welp, A. L. & Bomberger, J. M. Bacterial community interactions during chronic respiratory disease. Front. Cell. Infect. Microbiol.10, 213 (2020).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"77246_CR23","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","volume":"1","author":"F Ratjen","year":"2015","unstructured":"Ratjen, F. et al. Cystic fibrosis. Nat. Rev. Dis. Primer. 1 (1), 15010 (2015).","journal-title":"Nat. Rev. Dis. Primer"},{"issue":"18","key":"77246_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann, H. & Ratjen, F. Cystic fibrosis. N Engl. J. Med.389 (18), 1693\u20131707 (2023).","journal-title":"N Engl. J. Med."},{"issue":"2","key":"77246_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani, C. et al. ECFS best practice guidelines: the 2018 revision. J. Cyst. Fibros.17 (2), 153\u2013178 (2018).","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"77246_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","volume":"11","author":"N Mayer-Hamblett","year":"2023","unstructured":"Mayer-Hamblett, N. et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med.11 (4), 329\u2013340 (2023).","journal-title":"Lancet Respir Med."},{"issue":"9","key":"77246_CR27","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/thoraxjnl-2019-214187","volume":"75","author":"MT Nelson","year":"2020","unstructured":"Nelson, M. T. et al. Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome. Thorax. 75 (9), 780\u2013790 (2020).","journal-title":"Thorax"},{"issue":"8","key":"77246_CR28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/thorax-2023-220100","volume":"78","author":"NJ Rowbotham","year":"2023","unstructured":"Rowbotham, N. J. et al. A refresh of the top 10 research priorities in cystic fibrosis. Thorax. 78 (8), 840\u2013843 (2023).","journal-title":"Thorax"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77246-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77246-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77246-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:16:40Z","timestamp":1732609000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77246-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77246"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77246-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29298"}}